Active Pharmaceutical Ingredient (API) Market in India 2024-2028

Report
137 Pages
February 2024
Region: India
TechNavio
ID: 5941990

The active pharmaceutical ingredient (API) market in India is forecasted to grow by USD 7.56 bn during 2023-2028, accelerating at a CAGR of 6.49% during the forecast period. The report on the active pharmaceutical ingredient (API) market in India provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increasing number of type II drug master files (DMF), a growing emphasis on biosimilar manufacturing, and a growing need to focus on core competencies.

The active pharmaceutical ingredient (API) market in India is segmented as below:

By Manufacturing Type

Captive APIs
Contract APIs

By Type

Innovative APIs
Generic APIs

By Product Type

Prescription
Over-the-counter (OTC)

This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredient (API) market in India growth during the next few years. Also, increasing patent exercises and adoption of sustainable and environmentally friendly manufacturing practices will lead to sizable demand in the market.

The report on the active pharmaceutical ingredient (API) market in India covers the following areas:

Active pharmaceutical ingredient (API) market in India sizing
Active pharmaceutical ingredient (API) market in India forecast
Active pharmaceutical ingredient (API) market in India industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (API) market in India vendors that include AbbVie Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Divis Laboratories Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., Hetero Labs Ltd., Ind Swift Laboratories Ltd., IOL Chemicals and Pharmaceuticals Ltd., Ipca Laboratories Ltd., JB Chemicals and Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Solara Active Pharma Sciences Ltd., Sun Pharmaceutical Industries Ltd., Suven Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.. Also, the active pharmaceutical ingredient (API) market in India analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market Segmentation by Manufacturing Type
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product Type
Exhibit 07: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 10: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 11: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 12: Chart on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 13: Data Table on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 14: Chart on India: Year-over-year growth 2023-2028 (%)
Exhibit 15: Data Table on India: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Active pharmaceutical ingredient (API) market in India 2018 - 2022
Exhibit 16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in India 2018 - 2022 ($ billion)
4.2 Manufacturing Type Segment Analysis 2018 - 2022
Exhibit 17: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 18: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.4 Product Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Type Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 26: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Manufacturing Type

6.1 Market segments
Exhibit 27: Chart on Manufacturing Type - Market share 2023-2028 (%)
Exhibit 28: Data Table on Manufacturing Type - Market share 2023-2028 (%)
6.2 Comparison by Manufacturing Type
Exhibit 29: Chart on Comparison by Manufacturing Type
Exhibit 30: Data Table on Comparison by Manufacturing Type
6.3 Captive APIs - Market size and forecast 2023-2028
Exhibit 31: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 32: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 33: Chart on Captive APIs - Year-over-year growth 2023-2028 (%)
Exhibit 34: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%)
6.4 Contract APIs - Market size and forecast 2023-2028
Exhibit 35: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 37: Chart on Contract APIs - Year-over-year growth 2023-2028 (%)
Exhibit 38: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Manufacturing Type
Exhibit 39: Market opportunity by Manufacturing Type ($ billion)
Exhibit 40: Data Table on Market opportunity by Manufacturing Type ($ billion)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 41: Chart on Type - Market share 2023-2028 (%)
Exhibit 42: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 43: Chart on Comparison by Type
Exhibit 44: Data Table on Comparison by Type
7.3 Innovative APIs - Market size and forecast 2023-2028
Exhibit 45: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 46: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%)
Exhibit 48: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%)
7.4 Generic APIs - Market size and forecast 2023-2028
Exhibit 49: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 51: Chart on Generic APIs - Year-over-year growth 2023-2028 (%)
Exhibit 52: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Type
Exhibit 53: Market opportunity by Type ($ billion)
Exhibit 54: Data Table on Market opportunity by Type ($ billion)

8 Market Segmentation by Product Type

8.1 Market segments
Exhibit 55: Chart on Product Type - Market share 2023-2028 (%)
Exhibit 56: Data Table on Product Type - Market share 2023-2028 (%)
8.2 Comparison by Product Type
Exhibit 57: Chart on Comparison by Product Type
Exhibit 58: Data Table on Comparison by Product Type
8.3 Prescription - Market size and forecast 2023-2028
Exhibit 59: Chart on Prescription - Market size and forecast 2023-2028 ($ billion)
Exhibit 60: Data Table on Prescription - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Chart on Prescription - Year-over-year growth 2023-2028 (%)
Exhibit 62: Data Table on Prescription - Year-over-year growth 2023-2028 (%)
8.4 Over-the-counter (OTC) - Market size and forecast 2023-2028
Exhibit 63: Chart on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion)
Exhibit 64: Data Table on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Chart on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%)
Exhibit 66: Data Table on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%)
8.5 Market opportunity by Product Type
Exhibit 67: Market opportunity by Product Type ($ billion)
Exhibit 68: Data Table on Market opportunity by Product Type ($ billion)

9 Customer Landscape

9.1 Customer landscape overview
Exhibit 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 70: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 71: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 72: Overview on factors of disruption
11.4 Industry risks
Exhibit 73: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 74: Vendors covered
12.2 Market positioning of vendors
Exhibit 75: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 76: AbbVie Inc. - Overview
Exhibit 77: AbbVie Inc. - Product / Service
Exhibit 78: AbbVie Inc. - Key news
Exhibit 79: AbbVie Inc. - Key offerings
12.4 Aurobindo Pharma Ltd.
Exhibit 80: Aurobindo Pharma Ltd. - Overview
Exhibit 81: Aurobindo Pharma Ltd. - Product / Service
Exhibit 82: Aurobindo Pharma Ltd. - Key offerings
12.5 Cadila Pharmaceuticals Ltd.
Exhibit 83: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 84: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 85: Cadila Pharmaceuticals Ltd. - Key offerings
12.6 Cipla Ltd.
Exhibit 86: Cipla Ltd. - Overview
Exhibit 87: Cipla Ltd. - Business segments
Exhibit 88: Cipla Ltd. - Key news
Exhibit 89: Cipla Ltd. - Key offerings
Exhibit 90: Cipla Ltd. - Segment focus
12.7 Divis Laboratories Ltd.
Exhibit 91: Divis Laboratories Ltd. - Overview
Exhibit 92: Divis Laboratories Ltd. - Product / Service
Exhibit 93: Divis Laboratories Ltd. - Key offerings
12.8 Dr Reddys Laboratories Ltd.
Exhibit 94: Dr Reddys Laboratories Ltd. - Overview
Exhibit 95: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 96: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 97: Dr Reddys Laboratories Ltd. - Segment focus
12.9 Glenmark Pharmaceuticals Ltd.
Exhibit 98: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 99: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 100: Glenmark Pharmaceuticals Ltd. - Key offerings
12.10 Granules India Ltd.
Exhibit 101: Granules India Ltd. - Overview
Exhibit 102: Granules India Ltd. - Product / Service
Exhibit 103: Granules India Ltd. - Key news
Exhibit 104: Granules India Ltd. - Key offerings
12.11 IOL Chemicals and Pharmaceuticals Ltd.
Exhibit 105: IOL Chemicals and Pharmaceuticals Ltd. - Overview
Exhibit 106: IOL Chemicals and Pharmaceuticals Ltd. - Business segments
Exhibit 107: IOL Chemicals and Pharmaceuticals Ltd. - Key offerings
Exhibit 108: IOL Chemicals and Pharmaceuticals Ltd. - Segment focus
12.12 Ipca Laboratories Ltd.
Exhibit 109: Ipca Laboratories Ltd. - Overview
Exhibit 110: Ipca Laboratories Ltd. - Product / Service
Exhibit 111: Ipca Laboratories Ltd. - Key offerings
12.13 Jubilant Pharmova Ltd.
Exhibit 112: Jubilant Pharmova Ltd. - Overview
Exhibit 113: Jubilant Pharmova Ltd. - Business segments
Exhibit 114: Jubilant Pharmova Ltd. - Key news
Exhibit 115: Jubilant Pharmova Ltd. - Key offerings
Exhibit 116: Jubilant Pharmova Ltd. - Segment focus
12.14 Laurus Labs Ltd.
Exhibit 117: Laurus Labs Ltd. - Overview
Exhibit 118: Laurus Labs Ltd. - Key offerings
12.15 Lupin Ltd.
Exhibit 119: Lupin Ltd. - Overview
Exhibit 120: Lupin Ltd. - Product / Service
Exhibit 121: Lupin Ltd. - Key news
Exhibit 122: Lupin Ltd. - Key offerings
12.16 Sun Pharmaceutical Industries Ltd.
Exhibit 123: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 124: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 125: Sun Pharmaceutical Industries Ltd. - Key news
Exhibit 126: Sun Pharmaceutical Industries Ltd. - Key offerings
12.17 Torrent Pharmaceuticals Ltd.
Exhibit 127: Torrent Pharmaceuticals Ltd. - Overview
Exhibit 128: Torrent Pharmaceuticals Ltd. - Business segments
Exhibit 129: Torrent Pharmaceuticals Ltd. - Key offerings
Exhibit 130: Torrent Pharmaceuticals Ltd. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 131: Inclusions checklist
Exhibit 132: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 133: Currency conversion rates for US$
13.4 Research methodology
Exhibit 134: Research methodology
Exhibit 135: Validation techniques employed for market sizing
Exhibit 136: Information sources
13.5 List of abbreviations
Exhibit 137: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market Segmentation by Manufacturing Type
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Product Type
Exhibits 7: Executive Summary - Chart on Vendor Market Positioning
Exhibits 8: Parent market
Exhibits 9: Market Characteristics
Exhibits 10: Offerings of vendors included in the market definition
Exhibits 11: Market segments
Exhibits 12: Chart on India - Market size and forecast 2023-2028 ($ billion)
Exhibits 13: Data Table on India - Market size and forecast 2023-2028 ($ billion)
Exhibits 14: Chart on India: Year-over-year growth 2023-2028 (%)
Exhibits 15: Data Table on India: Year-over-year growth 2023-2028 (%)
Exhibits 16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in India 2018 - 2022 ($ billion)
Exhibits 17: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion)
Exhibits 18: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - Product Type Segment 2018 - 2022 ($ billion)
Exhibits 20: Five forces analysis - Comparison between 2023 and 2028
Exhibits 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 23: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 24: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 25: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 26: Chart on Market condition - Five forces 2023 and 2028
Exhibits 27: Chart on Manufacturing Type - Market share 2023-2028 (%)
Exhibits 28: Data Table on Manufacturing Type - Market share 2023-2028 (%)
Exhibits 29: Chart on Comparison by Manufacturing Type
Exhibits 30: Data Table on Comparison by Manufacturing Type
Exhibits 31: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 32: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 33: Chart on Captive APIs - Year-over-year growth 2023-2028 (%)
Exhibits 34: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%)
Exhibits 35: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 37: Chart on Contract APIs - Year-over-year growth 2023-2028 (%)
Exhibits 38: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%)
Exhibits 39: Market opportunity by Manufacturing Type ($ billion)
Exhibits 40: Data Table on Market opportunity by Manufacturing Type ($ billion)
Exhibits 41: Chart on Type - Market share 2023-2028 (%)
Exhibits 42: Data Table on Type - Market share 2023-2028 (%)
Exhibits 43: Chart on Comparison by Type
Exhibits 44: Data Table on Comparison by Type
Exhibits 45: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 46: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 47: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%)
Exhibits 48: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%)
Exhibits 49: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 50: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion)
Exhibits 51: Chart on Generic APIs - Year-over-year growth 2023-2028 (%)
Exhibits 52: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%)
Exhibits 53: Market opportunity by Type ($ billion)
Exhibits 54: Data Table on Market opportunity by Type ($ billion)
Exhibits 55: Chart on Product Type - Market share 2023-2028 (%)
Exhibits 56: Data Table on Product Type - Market share 2023-2028 (%)
Exhibits 57: Chart on Comparison by Product Type
Exhibits 58: Data Table on Comparison by Product Type
Exhibits 59: Chart on Prescription - Market size and forecast 2023-2028 ($ billion)
Exhibits 60: Data Table on Prescription - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Chart on Prescription - Year-over-year growth 2023-2028 (%)
Exhibits 62: Data Table on Prescription - Year-over-year growth 2023-2028 (%)
Exhibits 63: Chart on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion)
Exhibits 64: Data Table on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion)
Exhibits 65: Chart on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%)
Exhibits 66: Data Table on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%)
Exhibits 67: Market opportunity by Product Type ($ billion)
Exhibits 68: Data Table on Market opportunity by Product Type ($ billion)
Exhibits 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 70: Impact of drivers and challenges in 2023 and 2028
Exhibits 71: Overview on Criticality of inputs and Factors of differentiation
Exhibits 72: Overview on factors of disruption
Exhibits 73: Impact of key risks on business
Exhibits 74: Vendors covered
Exhibits 75: Matrix on vendor position and classification
Exhibits 76: AbbVie Inc. - Overview
Exhibits 77: AbbVie Inc. - Product / Service
Exhibits 78: AbbVie Inc. - Key news
Exhibits 79: AbbVie Inc. - Key offerings
Exhibits 80: Aurobindo Pharma Ltd. - Overview
Exhibits 81: Aurobindo Pharma Ltd. - Product / Service
Exhibits 82: Aurobindo Pharma Ltd. - Key offerings
Exhibits 83: Cadila Pharmaceuticals Ltd. - Overview
Exhibits 84: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibits 85: Cadila Pharmaceuticals Ltd. - Key offerings
Exhibits 86: Cipla Ltd. - Overview
Exhibits 87: Cipla Ltd. - Business segments
Exhibits 88: Cipla Ltd. - Key news
Exhibits 89: Cipla Ltd. - Key offerings
Exhibits 90: Cipla Ltd. - Segment focus
Exhibits 91: Divis Laboratories Ltd. - Overview
Exhibits 92: Divis Laboratories Ltd. - Product / Service
Exhibits 93: Divis Laboratories Ltd. - Key offerings
Exhibits 94: Dr Reddys Laboratories Ltd. - Overview
Exhibits 95: Dr Reddys Laboratories Ltd. - Business segments
Exhibits 96: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits 97: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits 98: Glenmark Pharmaceuticals Ltd. - Overview
Exhibits 99: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibits 100: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibits 101: Granules India Ltd. - Overview
Exhibits 102: Granules India Ltd. - Product / Service
Exhibits 103: Granules India Ltd. - Key news
Exhibits 104: Granules India Ltd. - Key offerings
Exhibits 105: IOL Chemicals and Pharmaceuticals Ltd. - Overview
Exhibits 106: IOL Chemicals and Pharmaceuticals Ltd. - Business segments
Exhibits 107: IOL Chemicals and Pharmaceuticals Ltd. - Key offerings
Exhibits 108: IOL Chemicals and Pharmaceuticals Ltd. - Segment focus
Exhibits 109: Ipca Laboratories Ltd. - Overview
Exhibits 110: Ipca Laboratories Ltd. - Product / Service
Exhibits 111: Ipca Laboratories Ltd. - Key offerings
Exhibits 112: Jubilant Pharmova Ltd. - Overview
Exhibits 113: Jubilant Pharmova Ltd. - Business segments
Exhibits 114: Jubilant Pharmova Ltd. - Key news
Exhibits 115: Jubilant Pharmova Ltd. - Key offerings
Exhibits 116: Jubilant Pharmova Ltd. - Segment focus
Exhibits 117: Laurus Labs Ltd. - Overview
Exhibits 118: Laurus Labs Ltd. - Key offerings
Exhibits 119: Lupin Ltd. - Overview
Exhibits 120: Lupin Ltd. - Product / Service
Exhibits 121: Lupin Ltd. - Key news
Exhibits 122: Lupin Ltd. - Key offerings
Exhibits 123: Sun Pharmaceutical Industries Ltd. - Overview
Exhibits 124: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibits 125: Sun Pharmaceutical Industries Ltd. - Key news
Exhibits 126: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibits 127: Torrent Pharmaceuticals Ltd. - Overview
Exhibits 128: Torrent Pharmaceuticals Ltd. - Business segments
Exhibits 129: Torrent Pharmaceuticals Ltd. - Key offerings
Exhibits 130: Torrent Pharmaceuticals Ltd. - Segment focus
Exhibits 131: Inclusions checklist
Exhibits 132: Exclusions checklist
Exhibits 133: Currency conversion rates for US$
Exhibits 134: Research methodology
Exhibits 135: Validation techniques employed for market sizing
Exhibits 136: Information sources
Exhibits 137: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the active pharmaceutical ingredient (API) market in India: AbbVie Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Divis Laboratories Ltd., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., Hetero Labs Ltd., Ind Swift Laboratories Ltd., IOL Chemicals and Pharmaceuticals Ltd., Ipca Laboratories Ltd., JB Chemicals and Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Solara Active Pharma Sciences Ltd., Sun Pharmaceutical Industries Ltd., Suven Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is a paradigm shift in API manufacturing.'

According to the report, one of the major drivers for this market is the increasing number of type II drug master files (DMF).

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie Inc.
Aurobindo Pharma Ltd.
Cadila Pharmaceuticals Ltd.
Cipla Ltd.
Divis Laboratories Ltd.
Dr Reddys Laboratories Ltd.
Glenmark Pharmaceuticals Ltd.
Granules India Ltd.
Hetero Labs Ltd.
Ind Swift Laboratories Ltd.
IOL Chemicals and Pharmaceuticals Ltd.
Ipca Laboratories Ltd.
JB Chemicals and Pharmaceuticals Ltd.
Jubilant Pharmova Ltd.
Laurus Labs Ltd.
Lupin Ltd.
Solara Active Pharma Sciences Ltd.
Sun Pharmaceutical Industries Ltd.
Suven Pharmaceuticals Ltd.
Torrent Pharmaceuticals Ltd.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2513EUR$2,500USD£2,104GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4020EUR$4,000USD£3,366GBP

The active pharmaceutical ingredient (API) market in India is segmented as below:

By Manufacturing Type

By Type

By Product Type

The report on the active pharmaceutical ingredient (API) market in India covers the following areas:

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Related Topics

Related Reports

Ibuprofen Active Pharmaceutical Ingredient (API) Market 2024-2028

Active Pharmaceutical Ingredient (API) - Market Insights, Competitive Landscape, and Market Forecast - 2030

India Active Pharmaceutical Ingredients Market, By Region, Competition Forecast & Opportunities, 2020-2030F

Pharmaceutical API Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (captive, merchant), Synthesis (Synthetic, Biotech), Products (mAb, Hormones, Cytokines), Drug (OTC, Rx), Application (Diabetes, oncology, CVD) - Forecast to 2029